Professeur des Universités Praticien Hospitalier (PUPH)
Limoges University Hospital, Inserm U1248, University of Limoges
Jean-Baptiste Woillard has been a Doctor of Pharmacy since 2008. He obtained a Master in Pharmacology in 2007 followed by a PhD in Pharmacogenetics and Pharmacokinetics in 2011. He is currently Professor of Medical Pharmacology at the Faculty of Medicine of Limoges and is Head of the “Pharmacometrics and Artificial Intelligence” unit in the Department of Pharmacology, Toxicology and Pharmacovigilance (managed by Prof. Pierre Marquet) at Limoges University Hospital. He is a councilor of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and chair of the Pharmacometrics Committee, the European Association for Clinical Pharmacology and Therapeutics (EACPT) and of the French Society of Pharmacology and Therapeutics (SFPT). Prof Woillard conducts his research in the Inserm U1248 unit Pharmacology & Transplantation (Inserm is the French National Institute of Medical and Health Research) on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: pharmacogenetic and pharmacodynamic studies of IS; development of original models in pharmacokinetics; statistical modeling; and application to routine treatment personalization in transplant recipients. He is also interested in antibiotics modeling and their dose individualization. His new research focused on the application of machine learning methods to therapeutic drug monitoring and pharmacometrics. He received in 2020 the IFCC-Gérard Siest Young Scientist Award for Distinguished Contributions in Pharmacogenetics. He is leading a consortium of the French PEPR for which he obtained a grant of 1.8 M euros about the development of multiscale digital pharmacological twins. He published more than 100 publications in peer-reviewed, international journals, has done over 32 presentations in national and international congresses and has been invited to give 30 academic or industrial talks.
Disclosure(s): Astellas Pharma Inc.: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Chiesi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Gilead Sciences, Inc.: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)
Friday, March 29, 2024
1:30 PM – 2:30 PM MDT